Drug intelligence / Profile preview

NVX-144

Development stage: Preclinical
Lead developer: Novelix Pharmaceuticals
Modality: Small Molecules
Administration: Intramuscular

Overview

NVX-144 is a small molecule quinoxalinhydrazide derivative that serves as the parental lead compound for NVX-412. Developed by Novelix Pharmaceuticals, it is an antineoplastic agent that demonstrates potent cytotoxic activity against a variety of cancer types, particularly hematological malignancies. NVX-144 is the active pharmaceutical ingredient used to form NVX-412, which is a co-crystal of NVX-144 and oxalic acid designed to enhance its drug-like properties and pharmaceutical stability.

Other names: pyrazine-2-carboxylic acid N'-(7-fluoro-pyrrolo[1,2-a]quinoxalin-4-yl)hydrazide

Beyond the preview

Go deeper on NVX-144.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVX-144.

Explore the full profile